The Global Drug sales of Entresto stood at USD 4,644 Millions in 2022
The indicator recorded a historical growth (CAGR) of39% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Sacubitril and Valsartan (Entresto) is a fixed dose combination acts as an anti-hypertensive and cardiovascular agent. It is formulated as film coated tablets for oral route of administration. Entresto is indicated for the treatment of several indications in the cardiovascular therapy area.
Mechanism of Action
Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Sacubitril is an inhibitor of neutral endopeptidase inhibitor. NEP is an enzyme responsible for the breakdown of natriuretic peptides that can help to counteract many the physiologic and structural changes associated with heart failure.
Entresto Overview
Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction. Entresto also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. Entresto is indicated for the treatment of hypertension.
Entresto was first approved in 2015 and is sold globally including the US, the UK, France, Germany, and Japan by Novartis AG and its subsidiaries. Entresto drug sales recorded a mid-double digit Year on Year growth in 2022. Entresto drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
ACC 2021
At the 70th annual American College of Cardiology (ACC) 2021 meeting, results were presented for the PARADISE-MI trial which investigated whether Entresto (sacubitril/valstartan) decreases the risk of heart failure (HF) or cardiovascular (CV) death compared to an angiotensin-converting enzyme (ACE) inhibitor, Ramipril, in the enhanced risk acute myocardial infarction (AMI) population. Evidence from previous trials had demonstrated that Entresto was superior to the ACE inhibitor, Ramipril for patients who have symptomatic HF with reduced ejection faction (HFrEF), in term of reducing HF events and total mortality. PARADISE-MI missed its primary endpoint of a 15% reduction in HF events needed to demonstrate superiority of Entresto, first-in-class angiotensin receptor neprilysin inhibitor (ARNI) over Ramipril, in the AMI participant population. However, overall, there was an observed 10% reduction (p=0.17) n the Entresto group and positive reports of a reduced number of HF events by investigators of the trial.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward